MXPA04012568A - Vacuna que comprende mezclas de vesiculas de membrana externa meningococales multivalentes. - Google Patents
Vacuna que comprende mezclas de vesiculas de membrana externa meningococales multivalentes.Info
- Publication number
- MXPA04012568A MXPA04012568A MXPA04012568A MXPA04012568A MXPA04012568A MX PA04012568 A MXPA04012568 A MX PA04012568A MX PA04012568 A MXPA04012568 A MX PA04012568A MX PA04012568 A MXPA04012568 A MX PA04012568A MX PA04012568 A MXPA04012568 A MX PA04012568A
- Authority
- MX
- Mexico
- Prior art keywords
- meningococcal
- strain
- bactericidal activity
- ampoule
- derived
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 239000012528 membrane Substances 0.000 title description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 79
- 208000002352 blister Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 239000003708 ampul Substances 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 24
- 101710116435 Outer membrane protein Proteins 0.000 claims description 22
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000002950 deficient Effects 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241001212279 Neisseriales Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 38
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 11
- 241000588653 Neisseria Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 8
- 208000037941 meningococcal disease Diseases 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229920002704 polyhistidine Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- AZXKALLRCOCGBV-UHFFFAOYSA-N 1-phenyl-2-(propan-2-ylamino)hexan-1-one Chemical compound CCCCC(NC(C)C)C(=O)C1=CC=CC=C1 AZXKALLRCOCGBV-UHFFFAOYSA-N 0.000 description 3
- 101710164918 Choline-binding protein Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000009021 pre-vaccination Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 101100453077 Botryococcus braunii HDR gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 2
- 101710183389 Pneumolysin Proteins 0.000 description 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 101150095079 menB gene Proteins 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100420868 Anuroctonus phaiodactylus phtx gene Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000874355 Escherichia coli (strain K12) Outer membrane protein assembly factor BamA Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101000873843 Homo sapiens Sorting and assembly machinery component 50 homolog Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001244708 Moroccan pepper virus Species 0.000 description 1
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 101710110023 Putative adhesin Proteins 0.000 description 1
- 102100035853 Sorting and assembly machinery component 50 homolog Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 108091016312 choline binding proteins Proteins 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150020377 crtA gene Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108700039582 histidine triad Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940014135 meningitis vaccine Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150101515 tbpl2 gene Proteins 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0213622.4A GB0213622D0 (en) | 2002-06-13 | 2002-06-13 | Vaccine Corporation |
| PCT/EP2003/006094 WO2003105890A2 (en) | 2002-06-13 | 2003-06-10 | Vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04012568A true MXPA04012568A (es) | 2005-09-21 |
Family
ID=9938532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04012568A MXPA04012568A (es) | 2002-06-13 | 2003-06-10 | Vacuna que comprende mezclas de vesiculas de membrana externa meningococales multivalentes. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060110412A1 (https=) |
| EP (1) | EP1565211A2 (https=) |
| JP (1) | JP2005531614A (https=) |
| KR (1) | KR20050049431A (https=) |
| CN (1) | CN100387298C (https=) |
| AR (1) | AR040204A1 (https=) |
| AU (1) | AU2003236734A1 (https=) |
| BR (1) | BR0311777A (https=) |
| CA (1) | CA2488782A1 (https=) |
| CL (1) | CL2003001192A1 (https=) |
| CU (1) | CU23552A1 (https=) |
| GB (1) | GB0213622D0 (https=) |
| MX (1) | MXPA04012568A (https=) |
| NO (1) | NO20050132L (https=) |
| NZ (1) | NZ560766A (https=) |
| PE (1) | PE20040562A1 (https=) |
| RU (1) | RU2005100509A (https=) |
| UY (1) | UY27843A1 (https=) |
| WO (1) | WO2003105890A2 (https=) |
| ZA (1) | ZA200409547B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936261B2 (en) | 2000-07-27 | 2005-08-30 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
| GB2414667A (en) * | 2004-06-03 | 2005-12-07 | Isis Innovation | Vaccine compositions of N. meningitidis PorA and FetA antigens |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| ES2616294T3 (es) | 2005-01-27 | 2017-06-12 | Children's Hospital & Research Center At Oakland | Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis |
| PL1973564T3 (pl) * | 2005-12-22 | 2017-04-28 | Glaxosmithkline Biologicals S.A. | Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae |
| US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
| WO2009050586A1 (en) | 2007-10-19 | 2009-04-23 | Novartis Ag | Meningococcal vaccine formulations |
| EP2217250A4 (en) | 2007-11-09 | 2011-01-05 | California Inst Of Techn | IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS |
| EP2235531B1 (en) * | 2008-02-01 | 2015-01-14 | Sanofi Pasteur Limited | Assay for diagnosing streptococcus pneumoniae |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| JP2012512240A (ja) | 2008-12-17 | 2012-05-31 | ノバルティス アーゲー | ヘモグロビン受容体を含む髄膜炎菌ワクチン |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| JP5860402B2 (ja) * | 2009-10-08 | 2016-02-16 | イオン メディックス インコーポレイテッド | 室内空気由来細胞外ベシクルを含む組成物及びその用途 |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| CN102802664B (zh) * | 2009-12-22 | 2017-04-05 | 赛诺菲巴斯德有限公司 | 免疫原性组合物 |
| CN102802662A (zh) | 2010-03-18 | 2012-11-28 | 诺华有限公司 | 用于脑膜炎球菌血清组b的含佐剂疫苗 |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| WO2011127302A2 (en) * | 2010-04-07 | 2011-10-13 | Yue Shen | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
| BR112013005626B1 (pt) * | 2010-09-10 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição |
| EP2707009A1 (en) | 2011-05-12 | 2014-03-19 | Novartis AG | Antipyretics to enhance tolerability of vesicle-based vaccines |
| EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR |
| JP5957541B2 (ja) | 2012-02-02 | 2016-07-27 | ノバルティス アーゲー | 髄膜炎菌における増加したタンパク質発現のためのプロモータ |
| JP2015517089A (ja) | 2012-03-08 | 2015-06-18 | ノバルティス アーゲー | タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ |
| MX357538B (es) | 2012-06-14 | 2018-07-13 | Novartis Ag | Vacunas para meningococo de serogrupo x. |
| US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
| WO2016201342A1 (en) | 2015-06-10 | 2016-12-15 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| EP3484441A4 (en) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | GLYCOLIPID COMPOSITIONS AND METHOD FOR USE |
| US12161707B2 (en) | 2016-09-02 | 2024-12-10 | Glaxosmithkline Biologicals Sa | Vaccines for Neisseria gonorrhoeae |
| AU2021364838A1 (en) * | 2020-10-23 | 2023-06-08 | Omvax, Inc. | Compositions and methods for vaccination against neisseria gonorrhoeae |
| GB202115077D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Assay |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL338146A1 (en) * | 1997-07-17 | 2000-09-25 | North American Vaccine | Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide |
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| US6936261B2 (en) * | 2000-07-27 | 2005-08-30 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
-
2002
- 2002-06-13 GB GBGB0213622.4A patent/GB0213622D0/en not_active Ceased
-
2003
- 2003-06-10 RU RU2005100509/13A patent/RU2005100509A/ru not_active Application Discontinuation
- 2003-06-10 CL CL200301192A patent/CL2003001192A1/es unknown
- 2003-06-10 EP EP03735599A patent/EP1565211A2/en not_active Ceased
- 2003-06-10 CN CNB038162822A patent/CN100387298C/zh not_active Expired - Fee Related
- 2003-06-10 JP JP2004512791A patent/JP2005531614A/ja active Pending
- 2003-06-10 CA CA002488782A patent/CA2488782A1/en not_active Abandoned
- 2003-06-10 US US10/529,064 patent/US20060110412A1/en not_active Abandoned
- 2003-06-10 MX MXPA04012568A patent/MXPA04012568A/es not_active Application Discontinuation
- 2003-06-10 BR BR0311777-4A patent/BR0311777A/pt not_active IP Right Cessation
- 2003-06-10 KR KR1020047019991A patent/KR20050049431A/ko not_active Ceased
- 2003-06-10 WO PCT/EP2003/006094 patent/WO2003105890A2/en not_active Ceased
- 2003-06-10 NZ NZ560766A patent/NZ560766A/en not_active IP Right Cessation
- 2003-06-10 AU AU2003236734A patent/AU2003236734A1/en not_active Abandoned
- 2003-06-11 AR ARP030102096A patent/AR040204A1/es not_active Application Discontinuation
- 2003-06-11 UY UY27843A patent/UY27843A1/es unknown
- 2003-06-11 PE PE2003000583A patent/PE20040562A1/es not_active Application Discontinuation
-
2004
- 2004-11-25 ZA ZA200409547A patent/ZA200409547B/en unknown
- 2004-12-10 CU CU20040285A patent/CU23552A1/es active IP Right Grant
-
2005
- 2005-01-11 NO NO20050132A patent/NO20050132L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2488782A1 (en) | 2003-12-24 |
| WO2003105890A2 (en) | 2003-12-24 |
| AR040204A1 (es) | 2005-03-16 |
| CU23552A1 (es) | 2010-07-20 |
| RU2005100509A (ru) | 2006-06-10 |
| GB0213622D0 (en) | 2002-07-24 |
| NO20050132L (no) | 2005-02-11 |
| BR0311777A (pt) | 2005-03-29 |
| AU2003236734A1 (en) | 2003-12-31 |
| PE20040562A1 (es) | 2004-10-19 |
| UY27843A1 (es) | 2003-12-31 |
| WO2003105890A3 (en) | 2004-03-25 |
| CN1668329A (zh) | 2005-09-14 |
| CN100387298C (zh) | 2008-05-14 |
| US20060110412A1 (en) | 2006-05-25 |
| CL2003001192A1 (es) | 2005-01-07 |
| ZA200409547B (en) | 2006-07-26 |
| KR20050049431A (ko) | 2005-05-25 |
| NO20050132D0 (no) | 2005-01-11 |
| JP2005531614A (ja) | 2005-10-20 |
| EP1565211A2 (en) | 2005-08-24 |
| NZ560766A (en) | 2009-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100387298C (zh) | 疫苗组合物 | |
| TWI360424B (en) | Vaccine | |
| ES2337309T3 (es) | Vacuna. | |
| US20170209562A1 (en) | Immunogenic composition | |
| Perrett et al. | Towards an improved serogroup B Neisseria meningitidis vaccine | |
| EP1572729B1 (en) | Mutant frpb protein and refolding method | |
| US20100129387A1 (en) | Pharmaceutical composition containing the nmb0606 protein | |
| BRPI0710064A2 (pt) | composição farmacêutica contendo a proteìna nmb0938 | |
| Serino et al. | Meningococcal diseases: From genomes to vaccines | |
| BRPI0620867A2 (pt) | formulações farmacêuticas que contêm a proteìna nma0939 | |
| Pollard et al. | Meningococcal Conjugate and Protein-Based Vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |